Bioventus Inc.
BVS · NASDAQ
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.65 | -0.04 | -0.04 | 11.38 |
| FCF Yield | 6.65% | 5.61% | -3.38% | 2.73% |
| EV / EBITDA | 36.41 | 25.41 | 57.60 | 45.36 |
| Quality | ||||
| ROIC | 1.75% | 2.93% | 0.85% | -2.01% |
| Gross Margin | 67.96% | 69.14% | 67.05% | 66.82% |
| Cash Conversion Ratio | 9.54 | 2.80 | 5.82 | -60.76 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.90% | 3.38% | 3.38% | 3.83% |
| Free Cash Flow Growth | 17.30% | 225.29% | -207.52% | 82.87% |
| Safety | ||||
| Net Debt / EBITDA | -2.71 | 10.33 | 20.25 | 13.59 |
| Interest Coverage | 1.82 | 2.45 | 0.65 | 0.89 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.47 | 0.43 | 0.55 |
| Cash Conversion Cycle | 225.71 | 223.31 | 250.82 | 196.04 |